title: Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
abstract: Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrates short-term bexarotene treatment clearing preexisting β-amyloid deposits from the brains of APP/PS1ΔE9 mice with low amyloid burden, providing a rationale for repurposing this anticancer agent as an Alzheimer's disease (AD) therapeutic. Using a nearly identical treatment regimen, we were unable to detect any evidence of drug efficacy despite demonstration of target engagement.
authors.affiliation: Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, University of Florida College of Medicine, 1275 Center Drive, Gainesville, FL 32610, USA.
authors.forename: Ashleigh R
authors.initials: AR
authors.lastname: Price
authors.forename: Guilian
authors.initials: G
authors.lastname: Xu
authors.forename: Zoe B
authors.initials: ZB
authors.lastname: Siemienski
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Smithson
authors.forename: David R
authors.initials: DR
authors.lastname: Borchelt
authors.forename: Todd E
authors.initials: TE
authors.lastname: Golde
authors.forename: Kevin M
authors.initials: KM
authors.lastname: Felsenstein
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism*; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D001057:Apolipoproteins E / Q000378:metabolism*; D001921:Brain / Q000378:metabolism*; D008297:Male; D013764:Tetrahydronaphthalenes / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D016229:Amyloid beta-Peptides; D001057:Apolipoproteins E; D013764:Tetrahydronaphthalenes